VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Wednesday, January 7, 2026
Stock Comparison
Amgen Inc. vs Interactive Brokers Group, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Amgen Inc.
AMGN · Nasdaq Stock Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Interactive Brokers Group, Inc.
IBKR · NASDAQ
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Interactive Brokers Group, Inc.'s moat claims, evidence, and risks.
View IBKR analysisComparison highlights
- Moat score gap: Amgen Inc. leads (70 / 100 vs 60 / 100 for Interactive Brokers Group, Inc.).
- Segment focus: Amgen Inc. has 3 segments (80.1% in Core Innovative Medicines); Interactive Brokers Group, Inc. has 1 segment (100% in Electronic brokerage).
- Primary market structure: Competitive vs Competitive. Pricing power: Moderate vs Weak.
- Moat breadth: Amgen Inc. has 5 moat types across 3 domains; Interactive Brokers Group, Inc. has 4 across 4.
Primary market context
Amgen Inc.
Core Innovative Medicines
Branded biopharmaceutical therapies for common diseases (bone health, inflammation, oncology, cardiovascular and other specialty areas)
Global
Payers, providers, and pharmacies
Drug developer/manufacturer
80.1%
Interactive Brokers Group, Inc.
Electronic brokerage
Multi-asset electronic brokerage, clearing, custody, and financing (self-directed and institutional)
Global
Individual investors and institutional clients (e.g., hedge funds, advisors, proprietary trading firms, introducing brokers)
Broker-dealer / clearing broker / platform operator
100%
Side-by-side metrics
Moat coverage
Shared moat types
No overlap yet.
Amgen Inc. strengths
Interactive Brokers Group, Inc. strengths
Segment mix
Amgen Inc. segments
Full profile >Core Innovative Medicines
Competitive
Rare Disease Portfolio (Horizon + others)
Quasi-Monopoly
Biosimilars
Oligopoly
Interactive Brokers Group, Inc. segments
Full profile >Electronic brokerage
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.